|
|
Volumn 35, Issue 34, 2017, Pages 3807-3814
|
|
Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials
b
a
d
f
g
h
i
k
l
m
j
n
e
o
o
p
a,c
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALANINE AMINOTRANSFERASE;
ASPARTATE AMINOTRANSFERASE;
CORTICOSTEROID;
IPILIMUMAB;
NIVOLUMAB;
TRIACYLGLYCEROL LIPASE;
MONOCLONAL ANTIBODY;
ADRENAL CORTEX INSUFFICIENCY;
ADVANCED CANCER;
ADVERSE DRUG REACTION;
ALANINE AMINOTRANSFERASE BLOOD LEVEL;
ARTICLE;
ASPARTATE AMINOTRANSFERASE BLOOD LEVEL;
AUTOIMMUNE DISEASE;
CANCER COMBINATION CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER SURVIVAL;
CAUSE OF DEATH;
CLINICAL OUTCOME;
COLITIS;
CONNECTIVE TISSUE DISEASE;
CONTROLLED STUDY;
CORTICOSTEROID THERAPY;
DIARRHEA;
DRUG EFFICACY;
DRUG SAFETY;
DRUG WITHDRAWAL;
FOLLOW UP;
HEART VENTRICLE ARRHYTHMIA;
HEPATITIS;
HUMAN;
HYPOPITUITARISM;
HYPOTHYROIDISM;
IATROGENIC DISEASE;
INDUCTION CHEMOTHERAPY;
KIDNEY DISEASE;
LIVER TOXICITY;
MAINTENANCE CHEMOTHERAPY;
MAJOR CLINICAL STUDY;
MEDIASTINUM DISEASE;
MELANOMA;
METABOLIC DISORDER;
MONOTHERAPY;
MUSCULOSKELETAL DISEASE;
NEUROLOGIC DISEASE;
NUTRITIONAL DISORDER;
OVERALL SURVIVAL;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PNEUMONIA;
PNEUMOTHORAX;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
SIDE EFFECT;
SKIN DISEASE;
SYSTEMIC THERAPY;
TRIACYLGLYCEROL LIPASE BLOOD LEVEL;
UROGENITAL TRACT DISEASE;
CANCER STAGING;
COMBINATION DRUG THERAPY;
DISEASE FREE SURVIVAL;
DOSE RESPONSE;
DRUG ADMINISTRATION;
EVALUATION STUDY;
FACTUAL DATABASE;
FEMALE;
KAPLAN MEIER METHOD;
MALE;
MORTALITY;
NONPARAMETRIC TEST;
PATHOLOGY;
PATIENT SAFETY;
PROGNOSIS;
PROPORTIONAL HAZARDS MODEL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RETROSPECTIVE STUDY;
SKIN TUMOR;
STATISTICS AND NUMERICAL DATA;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
TREATMENT WITHDRAWAL;
TUMOR INVASION;
ANTIBODIES, MONOCLONAL;
CLINICAL TRIALS, PHASE II AS TOPIC;
CLINICAL TRIALS, PHASE III AS TOPIC;
DATABASES, FACTUAL;
DISEASE-FREE SURVIVAL;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
DRUG THERAPY, COMBINATION;
FEMALE;
HUMANS;
IPILIMUMAB;
KAPLAN-MEIER ESTIMATE;
MALE;
MELANOMA;
NEOPLASM INVASIVENESS;
NEOPLASM STAGING;
PATIENT SAFETY;
PROGNOSIS;
PROPORTIONAL HAZARDS MODELS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RETROSPECTIVE STUDIES;
SKIN NEOPLASMS;
STATISTICS, NONPARAMETRIC;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
WITHHOLDING TREATMENT;
|
|
EID: 85034023934
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2017.73.2289 Document Type: Article |
|
Times cited : (345)
|
|
References (15)
|
